2009
Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway
Li J, Sha X, LoRusso P. Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway. Journal Of Clinical Oncology 2009, 27: e14556-e14556. DOI: 10.1200/jco.2009.27.15_suppl.e14556.Peer-Reviewed Original ResearchGenetic variantsMetabolic pathwaysDNA break repairABT-888Significant genetic variantsTherapeutic outcomesBreak repairCytochrome P450Ongoing phase I trialMolecular basisWild-type CYP2D6Advanced solid tumorsPhase I trialRecombinant human cytochrome P450DNA damageHuman liver microsomesMetabolite formationVariant enzymeMultiple cytotoxic agentsTumor drug concentrationsPARP activityFunctional significanceMajor enzymePredominant enzymeHuman cytochrome P450
1996
Levels of 5‐hydroxymethyl‐2′‐deoxyuridine in DNA from blood as a marker of breast cancer
Djuric Z, Heilbrun L, Simon M, Smith D, Luongo D, LoRusso P, Martino S. Levels of 5‐hydroxymethyl‐2′‐deoxyuridine in DNA from blood as a marker of breast cancer. Cancer 1996, 77: 691-696. PMID: 8616761, DOI: 10.1002/(sici)1097-0142(19960215)77:4<691::aid-cncr15>3.0.co;2-w.Peer-Reviewed Original Research